Clopidogrel teva

What Is Clopidogrel?
Clopidogrel bisulfate (brand name: Plavix®) has been licensed to help prevent harmful blood clots from forming in people who have:

* Had a recent heart attack.
* Had a recent stroke.
* Severe leg pain due to a condition called peripheral artery disease (PAD).
* Been hosptialized with chest pain from unstable angina or have had a certain type of heart attack. These conditions are often known as acute coronary syndrome.

Heart Attack
Clopidogrel teva has been proven in large clinical trials to reduce the risk of future harmful blood clots forming in people who have had a recent heart attack. Clopidogrel is often used in combination with other medications to further reduce the risk of another heart attack. These often include cholesterol-lowering medications, aspirin, and blood pressure medications.

Stroke
Clopidogrel teva has been proven in clinical trials to reduce the risk of having another stroke. When harmful clots block blood vessels and decrease the blood supply to the brain, this is called an ischemic stroke. Clopidogrel helps prevent this from reoccurring. However, clopidogrel is not useful in patients with a type of stroke called a hemorrhagic stroke, which is caused by bleeding into the brain.

Clopidogrel teva

Clopidogrel teva Bisulfate is a potent oral antiplatelet agent often used in the treatment of coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It works by blocking a receptor called P2Y12. It is also used, along with aspirin, for the prevention of thromboembolism after placement of intra-coronary stent, PTCA and other invasive operations in the cardiovascular system.
Clopidogrel Bisulfate is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the brand name Plavix and considered to be blockbuster. Plavix tablets contain 97.875 mg of Clopidogrel Bisulfate which is the molar equivalent of 75 mg of Clopidogrel base.
Platelet aggregation is important in haemostasis (Blood Products Plasma Expanders and Haemostatics) and is also involved in thrombus formation, particularly in the arterial circulation. Anti-platelet drugs reduce platelet aggregation and are used to prevent further thromboembolic events in patients who have suffered myocardial infarction, ischaemic stroke or transient ischaemic attacks, or unstable angina, and for primary prevention of a thromboembolic event in patients at risk. Some are also used for the prevention of reocclusion or restenosis following angioplasty and bypass procedures. Anti-platelet drugs act through a wide range of mechanisms.